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Efficient Gene Disruption in Diverse Strains of Toxoplasma gondii
Using CRISPR/CAS9
Bang Shen, Kevin M. Brown, Tobie D. Lee, L. David Sibley
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA
ABSTRACT Toxoplasma gondii has become a model for studying the phylum Apicomplexa, in part due to the availability of excel-
lent genetic tools. Although reverse genetic tools are available in a few widely utilized laboratory strains, they rely on special ge-
netic backgrounds that are not easily implemented in natural isolates. Recent progress in modifying CRISPR (clustered regularly
interspaced short palindromic repeats), a system of DNA recognition used as a defense mechanism in bacteria and archaea, has
led to extremely efficient gene disruption in a variety of organisms. Here we utilized a CRISPR/CAS9-based system with single
guide RNAs to disrupt genes in T. gondii. CRISPR/CAS9 provided an extremely efficient system for targeted gene disruption and
for site-specific insertion of selectable markers through homologous recombination. CRISPR/CAS9 also facilitated site-specific
insertion in the absence of homology, thus increasing the utility of this approach over existing technology. We then tested
whether CRISPR/CAS9 would enable efficient transformation of a natural isolate. Using CRISPR/CAS9, we were able to rapidly
generate both rop18 knockouts and complemented lines in the type I GT1 strain, which has been used for forward genetic crosses
but which remains refractory to reverse genetic approaches. Assessment of their phenotypes in vivo revealed that ROP18 con-
tributed a greater proportion to acute pathogenesis in GT1 than in the laboratory type I RH strain. Thus, CRISPR/CAS9 extends
reverse genetic techniques to diverse isolates of T. gondii, allowing exploration of a much wider spectrum of biological diversity.
IMPORTANCE Genetic approaches have proven very powerful for studying the biology of organisms, including microbes. How-
ever, ease of genetic manipulation varies widely among isolates, with common lab isolates often being the most amenable to such
approaches. Unfortunately, such common lab isolates have also been passaged frequently in vitro and have thus lost many of the
attributes of wild isolates, often affecting important traits, like virulence. On the other hand, wild isolates are often not amenable
to standard genetic approaches, thus limiting inquiry about the genetic basis of biological diversity. Here we imported a new
genetic system based on CRISPR/CAS9, which allows high efficiency of targeted gene disruption in natural isolates of T. gondii.
This advance promises to bring the power of genetics to bear on the broad diversity of T. gondii strains that have been described
recently.
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The protozoan parasite Toxoplasma gondii is an obligate intra-cellular pathogen belonging to the phylum Apicomplexa,
which containsmany other important pathogens (such asPlasmo-
dium spp. andCryptosporidium spp.) of humans and livestock (1).
Due to the ease of growth in tissue culture and availability of tools
for forward and reverse genetics, T. gondii has become the model
organism for the study of apicomplexan parasites. InNorthAmer-
ican and Europe, Toxoplasma displays a highly clonal population
structure (2), members of which differ greatly in their acute viru-
lence in laboratorymice (2). Forward genetic approaches based on
genetic crosses between these lineages have shown that a family of
secreted serine threonine kinases largely controls differences in
acute virulence of T. gondii in the mouse (3). Reverse genetic ap-
proaches have been used to validate the role of these effectors in
selected laboratory strains (3). However, establishing to what ex-
tent these virulence factors contribute to pathogenesis in other
related clonal strains, and in much more diverse strains that have
been shown to exist in other regions of theworld (4), has remained
challenging.
Despite the availability of efficient systems for reverse genetics,
homologous integration is not the preferredmechanism for inser-
tion of foreignDNA into the genome ofT. gondii. Instead, DNA is
inserted into the genome randomly throughnonhomologous-end
joining (NHEJ). Inactivating the NHEJ pathway by knocking out
the critical component KU80 has been used for increasing the
efficiency of homologous recombination, thus facilitating gene
knockouts and tagging endogenous loci in T. gondii (5, 6). Al-
though this approach has clear advantages, it is limited to certain
genetic backgrounds where KU80 has been deleted (5, 7). The lack
of convenient genetic tools in many other T. gondii strains has
hindered our understanding of the wider role that conserved
genes play in diverse lineages. For example, the gene encoding the
serine threonine kinase ROP18 was identified as the major gene
responsible for differences between the highly virulent type I GT1
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strain and the nonvirulent type III CTG strain (8). Confirmation
of this role was based on a very strong gain of function when the
type I allele of ROP18 from theRH strainwas expressed in the type
III CTG strain (8). In contrast, a rop18 deletion in the type I RH
background causes only a modest loss of virulence (9). Although
this apparent discrepancy may be due to underlying differences
between type I strains, as described previously (10, 11), we have
not been able to test this hypothesis due to difficulty in knocking
out the ROP18 locus in the GT1 strain using conventional ap-
proaches.
CRISPR (clustered regularly interspaced short palindromic re-
peats) is a naturally occurring adaptive immune system found in
bacteria and archaea, where it operates to restrict mobile genetic
elements, such as bacteriophages and plasmids (12). Recently, the
CRISPR/CAS9 (CRISPR-associated gene 9) system was adapted
for targeted genome editing in a variety of organisms (13). The
type II CRISPR system from Streptococcus pyogenes is the most
commonly used for this purpose due to its well-known mecha-
nism of action (14). When in complex with CRISPR RNA and a
transactivating RNA, the endonuclease CAS9 introduces double-
strand DNA breaks in a target sequence that is homologous to
CRISPR RNA, and these breaks can be repaired by NHEJ or ho-
mologous recombination (14). The CAS9 nuclease is also able to
use a hybrid single guide RNA (sgRNA) made from the fusion of
20-nucleotide CRISPR RNA to the transactivating RNA scaffold
to generate double-strand breaks in the target DNA (14). The
utility of using sgRNAs designed to target specific genes combined
with the high efficiency by disruption by CRISPR/CAS9 has
proven useful for gene manipulation in many model organisms
(15–20).
In the present study, we adapted the CRISPR/CAS9 system for
efficient gene disruption in T. gondii. We used CAS9 combined
with site-specific sgRNAs to disrupt the uracil phosphoribosyl
transferase (UPRT) gene. Loss of UPRT results in resistance to
fluorodeoxyribose (FUDR), thus allowing easy quantitation of the
efficiency and providing a convenient site for monitoring the fre-
quency of disruption. We extended the use of CRISPR/CAS9 to
disrupt the ROP18 locus from the type I strain GT1 and to com-
plement this loss at theUPRT locus, revealing that ROP18 plays a
larger role in acute virulence than previously predicted (9). Our
studies demonstrate that CAS9-mediated gene disruption pro-
vides an efficient and powerfulmeans of testing the role of specific
genes in diverse genetic backgrounds of T. gondii.
RESULTS
Introduction of site-specific mutations in the T. gondii genome
using CRISPR/CAS9. Previous studies have shown that combin-
ing CRISPR/CAS9 with sgRNAs can be used to generate site-
specific double-strand breaks in the target DNA that are repaired
by NHEJ, leading to short insertions and deletions that inactivate
the gene (20). To adapt the CRISPR/CAS9 system to T. gondii, we
constructed a plasmid expressing a nucleus-localized CAS9 fused
to green fluorescent protein (CAS9-NLS-GFP) driven by the
SAG1 promoter and a single guide RNA (sgRNA) driven by the
T. gondii U6 (TgU6) promoter (Fig. 1A; also, see Table S1 in the
supplemental material). The sgRNA contained a 20-nucleotide
(nt) guide RNA that targeted a region in exon 5 of theUPRT gene
immediately upstream of a protospacer-adjacent motif (PAM),
which consists of NGG for the S. pyogenes CAS9 nuclease (14)
(Fig. 1). We chose the UPRT locus to test the efficiency of the
FIG 1 CRISPR/CAS9-directed mutagenesis in T. gondii. (A) (Top) Schematic illustration of the plasmid expressing CAS9 and a single guide RNA (sgRNA)
targeting the UPRT gene in T. gondii. Detailed plasmid map and sequence files can be found in Fig. S1 in the supplemental material. CAS9 (from Streptococcus
pyogenes) fused toGFPwas expressed from the TgSAG1 promoter, and the sgRNAwas expressed from the TgU6 promoter. (Bottom) Sequence of the sgRNA and
the region targeted in UPRT (purple bar). The green arrowhead indicates the predicted cleavage site by CAS9. NLS, nuclear localization signal; PAM,
protospacer-adjacent motif. (B) Expression of CAS9-NLS-GFP in T. gondii determined by immunofluorescence staining 24 h after transfection of the CAS9/
sgUPRT plasmid. Parasites were stained with rabbit anti-TgALD (red), and CAS9-GFP was stained with mouse anti-GFP (green). Scale bar  5 m. (C)
Mutations in the UPRT gene induced by CAS9 and the sgUPRT from FUDR-resistant clones (MUT 1, etc., represent different clones).
Shen et al.
















CRISPR/CAS9 system because its inactivation leads to FUDR re-
sistance (21), providing a convenient assay for measuring gene
disruption. To assess the frequency of CRISPR/CAS9-mediated
gene inactivation in T. gondii, we transfected the UPRT-specific
sgRNA (sgUPRT) CRISPR plasmid into the type I RH strain by
electroporation. GFP expression was monitored to determine the
transfection efficiency at 24 h after electroporation, revealing that
~20 to 30% of cells received the plasmid (Fig. 1B and Table 1). To
check the frequency of UPRT inactivation, the pooled transfec-
tants (collected 48 h after electroporation) were subjected to
plaque assays with and without FUDR. Approximately 10% of the
successful transfectants (defined as CAS9-GFP-positive cells)
were FUDR resistant (Table 1). To confirm that FUDR-resistant
parasites had mutations in the UPRT gene, we generated single
clones and sequenced the targeted region. All the sequenced
clones had mutations in UPRT, primarily consisting of short de-
letions or insertions (Fig. 1C). As a control for the above-
described experiment, we replaced the UPRT-targeting sgRNA
with one that targeted ROP18 (sgROP18). Transfection of the
sgROP18 CRISPR plasmid resulted in a similar number of CAS9-
GFP-positive cells but did not result in FUDR-resistant parasites
(Table 1), indicating that CRISPR/CAS9-mediatedmutagenesis is
site specific. To further check the site specificity and potential
off-target activity, wemade two sgRNAs (OT1 andOT2) that each
differed from the UPRT-targeting sgRNA by two nucleotides (Ta-
ble 1). Transfection of these constructs produced similar levels of
CAS9-GFP-positive cells but 200- to 3,000-fold fewer FUDR-
resistant parasites (Table 1). Collectively, these results indicate
that CRISPR/CAS9 efficiently and specifically introduces targeted
mutations into T. gondii.
Gene disruption based on CRISPR/CAS9-induced homolo-
gous recombination. To expand the CRISPR system to target
genes for which no direct selection exists, we next sought to deter-
minewhether it could facilitate gene disruption by integration of a
selectable marker. We again targeted the UPRT locus, as it pro-
vided a convenient means to test the efficacy of integration. For
this experiment, we cotransfected the sgUPRT CRISPR plasmid
with a homology template consisting of an amplicon (DNA frag-
ments generated by PCR amplification) (see Tables S1 and S2 in
the supplemental material) containing a pyrimethamine-resistant
DHFR (DHFR*) cassette flanked by homology arms correspond-
ing to the regions directly surrounding the sgUPRT target se-
quence (Fig. 2A; also, see Tables S1 and S2). Following cotransfec-
tion, parasites were selected with pyrimethamine, and the stably
resistant pool was subjected to plaque assays with and without
FUDR. We observed that the majority (70% to 100%) of the
pyrimethamine-resistant parasites were also FUDR resistant, in-
dicating a high frequency of UPRT disruption (Table 2). To con-
firm that FUDR resistance was due to DHFR* insertion at the
UPRT locus, we isolated single clones of pyrimethamine-resistant
parasites (without FUDR selection) and performed diagnostic
PCR to check for integration (Fig. 2B). The majority (45%) of
these clones demonstrated correct integration of DHFR* into the
UPRT locus (Fig. 2B), where both the 5= and 3= flanks were con-
sistent with a double-crossover event by homologous recombina-
tion (Table 2). In other clones (15 to 20% of cases), the UPRT
locus was disrupted but only one of the two flanking regions
showed a pattern by PCR that was consistent with a simple
homologous-crossover event (Table 2). Although the exact nature
of these insertion events is unknown, 70% of clones showed
targeted disruption of theUPRT gene, indicating a high degree of
specific targeting (Table 2). In contrast, when parasites were trans-
fected with only the UPRT homology template but not the
sgUPRT plasmid, the pool of pyrimethamine-resistant parasites
did not yield FUDR-resistant plaques (Table 2), consistent with
the low frequency of homologous recombination in T. gondii.
Likewise, although transfection of parasites with an unrelated
gRNA (sgROP18) in combination with the UPRT-targeting
DHFR* amplicon gave parasites that were resistant to pyrimeth-
amine, it did not yield FUDR-resistant parasites (Table 2). Collec-
tively, these results indicate that CRISPR/CAS9 enhances local
recombination at the gRNA target region to introduce high-
frequency insertion, resulting in gene disruption.
Although gene disruption can be a powerfulmeans of assessing
gene function, it is limited by the possibility that regions upstream
of the insertion may still be transcribed, potentially leading to
truncated gene products being expressed. To test whether
CRISPR/CAS9 could be used to delete the entire coding sequence
of UPRT, we used the sgUPRT CRISPR plasmid in combination
with a homology template that contained DHFR* flanked by 5=
and 3= homology regions from outside the coding sequence of the
UPRT gene (Fig. 2C; also, see Table S1 in the supplemental mate-





% efficiencycWithout FUDR With FUDR
UPRT 1 41.0 92/200 122/6,000 11.0
2 26.5 73/200 65/6,000 11.3
3 21.6 70/200 39/6,000 8.6
ROP18 1 27.4 93/200 0/600,000 0.0
2 24.4 67/200 0/600,000 0.0
3 19.8 71/200 0/600,000 0.0
UPRT-OT1d 1 27.6 40/200 1/600,000 0.003
2 23.9 63/200 0/600,000 0.0
UPRT-OT2e 1 16.7 57/200 6/600,000 0.021
2 20.0 67/200 12/600,000 0.050
a The CAS9-GFP expressing population was estimated by immunofluorescence staining 24 h posttransfection.
b Number of plaques observed/number of parasites seeded. When applied, FUDR was used at 10 M.
c [(Number of plaques observed in the presence of FUDR/% GFP-positive cells)/number of plaques observed in the absence of FUDR] 100.
d The sgRNA sequence GGCGTCTCGATTGTGAGACG differs from the UPRT sgRNA sequence by two nucleotides (bold).
e The gRNA sequence GGCGTCTCGATTGTGAAGGC differs from the UPRT sgRNA sequence by two nucleotides (bold).
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rial). Following cotransfection of the sgUPRT plasmid with this
DHFR* amplicon, we selected with pyrimethamine and then
checked the frequency of FUDR resistance by plaque assay and
homologous replacement by PCR (Table 2). We observed a high
frequency of homologous recombination at the UPRT locus as
described above (Fig. 2D and Table 2). These findings indicate
that in addition to disruption of a gene by insertion, CRISPR/
CAS9 can also be used to delete large genomic regions by homol-
ogous recombination, using a single guide RNA to create a
double-strand break in the gene of interest.
CRISPR/CAS9 enhances site-specific nonhomologous inte-
grationof foreignDNA.Previous studies have shown that homol-
ogous recombination in T. gondii requires relatively long flanking
regions that match the genomic locus in order to ensure efficient
integration (5). To examine whether this requirement might also
limit the utility of CRISPR/CAS9, we explored the length of ho-
mology needed to drive efficient integration at the UPRT locus.
We compared the efficiency of targeting with long homology re-
gions (i.e., 750 to 900 bp) to that of using flanking regions of 20 bp,
in each case surrounding the DHFR* cassette (Fig. 3A). As a con-
FIG 2 CRISPR/CAS9-mediated gene disruption and/or deletion of the UPRT locus. (A) Schematic of CRISPR/CAS9 strategy used to inactivate UPRT by
inserting pyrimethamine-resistant DHFR (DHFR*). Transfection of the sgUPRT together with an amplicon containing a DHFR*-expressing cassette flanked by
homology regions to UPRT was used to generate gene disruptions by insertion. The purple bar in UPRT gene represents the region targeted by the sgRNA. (B)
Diagnostic PCR demonstrating homologous integration and gene disruption in a representative clone (uprt::DHFR*-I) compared with the parental line RH.
PCR1 and PCR2 provide evidence of homologous integration based on products amplified between the DHFR* gene and regions in the UPRT locus that lie
outside the targeting amplicon. PCR3 amplified a 1.2-kb fragment in wild-type cells that was lost due to the insertion of DHFR* (the larger fragment created by
insertion of DHFR* [4.4 kb] does not amplify under conditions described here). The purple bar in UPRT gene represents the region targeted by the sgRNA. (C)
Schematic of CRISPR/CAS9 strategy used to delete the entire coding region of UPRT by inserting DHFR*. Transfection of the sgUPRT together with the
DHFR*-expressing amplicon shown was used to generate gene deletions. (D) Diagnostic PCR demonstrating homologous integration and gene deletion in a
representative clone (uprt::DHFR*-D) compared with the parental line RH. PCR4 and PCR5 provide evidence of homologous integration based on products
amplified between the DHFR* gene and regions in the UPRT locus that lie outside the targeting amplicon. PCR3 was as described above.




















1 1 none —f 49/200 0/200,000 0.0 — —
2 none — 43/200 0/200,000 0.0 — —
2 1 UPRT Insertion 55/200 38/200 69.0 4/9 2/9
2 UPRT Insertion 64/200 50/200 78.1 4/6 1/6
3 UPRT Insertion 34/200 51/200 100.0 NDg ND
3 1 ROP18 — 75/200 0/200,000 0.0 — —
2 ROP18 — 47/200 0/200,000 0.0 — —
4 1 UPRT Deletion 45/200 50/200 100.0 4/9 5/9
2 UPRT Deletion 55/200 47/200 85.5 3/7 3/7
a Different homology templates were used for gene insertion or deletion as described for Fig. 2A and C.
b Number of plaques observed/number of parasites seeded. When used, FUDR was added to a final concentration of 10 M.
c (Number of plaques observed in the presence of FUDR/number of plaques observed in the absence of FUDR) 100.
d Number of positive clones/number of total clones checked. Clones that showed correct 5= integration (positive in PCR1 or PCR4), correct 3= integration (positive in PCR2 or
PCR5), and loss of the endogenous UPRT gene (negative in PCR3) were considered to have undergone complete homologous replacement events.
e Number of positive clones/number of total clones checked. Clones that showed loss of the endogenous UPRT gene (negative in PCR3) and correct integration in at least one end
(5= or 3= but not both) were considered to have undergone partial homologous replacement events.
f —, not applicable.
g ND, not determined.
Shen et al.
















trol, we transfected the sgUPRT plasmid along with a construct
containing the DHFR* selectable marker that lacked any homol-
ogy to the UPRT gene (Fig. 3A). Transfected parasites were se-
lected with pyrimethamine and then tested for FUDR resistance
by plaque assay. Regardless of the targeting construct used, we
observed high frequencies of parasites that were resistant to both
drugs, suggesting that the DHFR* cassette was integrated into the
UPRT gene. To further test the efficiency of integration, we ob-
tained pyrimethamine-resistant single clones (without FUDR se-
lection) and checked for integration into the UPRT locus by PCR
(Fig. 3B). We used the size of the PCR3 product instead of PCR1
and PCR2 (Fig. 2A) to examineDHFR* insertion, becauseDHFR*
may be incorporated at either orientation when short or no ho-
mology arms are used. For both the long (i.e., 750- to 900-bp) and
short (i.e., 20-bp) homology flanks, as well as for the DHFR* cas-
sette that lacked any homology, a high percentage (50%) of
clones demonstrated correct integration into theUPRT locus (Ta-
ble 3). These results indicate that CRISPR/CAS9 can also be used
to facilitate nonhomologous integration into specific sites that are
targeted for double-strand breaks using single guide RNAs, mak-
ing targeted gene disruption much easier.
CRISPR/CAS9-mediated gene disruption in diverse type I
strains. All the preceding experiments were done with the type I
RH strain, which is highly amenable to genetic manipulation but
not entirely representative of natural type I variants (11, 22). To
test whether CRISPR/CAS9 would allow broader application of
reverse genetic approaches, we attempted to knock out out a gene
in the type I strain GT1, which is a low-passage-number isolate
that retains the entire life cycle. For this test, we chose the ROP18
gene, which had previously been implicated in the virulence of the
type I strainGT1 (8). To disruptROP18, we designed a guide RNA
to target the 5= coding region ofROP18 (sgROP18) and paired this
with a PCR amplicon consisting of the DHFR* selectable marker
flanked with regions of homology to ROP18 (Fig. 4A). After
cotransfection of the sgROP18 CRISPR plasmid and homology
template into GT1, parasites were selected with pyrimethamine
and cloned by limiting dilutions. All six randomly selected
pyrimethamine-resistant clones were positive for correct integra-
FIG3 Role of flanking regions inCRISPR/CAS9-mediated gene disruption at theUPRT locus. (A) Schematic of CRISPR/CAS9 strategy used to inactivateUPRT
by inserting DHFR*. Transfection of the sgUPRT plasmid together with DHFR*-expressing amplicons that contained variable-length flanks with homology to
UPRT, or with no homology, were used to generate gene disruptions by insertion. The purple bar in UPRT gene represents the region targeted by the sgRNA. (B)
PCR3 analysis of the UPRT locus. Amplification of the endogenous locus (RH) yielded a band of 1.2 kb, while insertion of a single copy of DHFR* resulted in a
band of 4.4 kb (uprt::DHFR*). The clone shown was derived by cotransfection of an amplicon of DHFR* with no homology flanks.

















1 1 UPRT Insertion 750, 900 72/200 65/200 90.3 3/5 2/5
2 UPRT Insertion 750, 900 86/200 76/200 88.4 NDf ND
2 1 UPRT Insertion 20, 20 25/200 22/200 88.0 3/5 2/5
2 UPRT Insertion 20, 20 53/200 49/200 92.5 4/6 1/6
3 1 UPRT Insertion 0, 0 32/200 24/200 75.0 3/8 2/8
2 UPRT Insertion 0, 0 52/200 37/200 71.2 4/5 1/5
a The sizes of the fragments flanking the 5= and 3= ends of DHFR that are homologous to UPRT, as indicated in Fig. 3A.
b Number of plaques observed/number of parasites seeded. When used, FUDR was added to a final concentration of 10 M.
c (Number of plaques observed in the presence of FUDR [10 M]/number of plaques observed in the absence of FUDR) 100.
d Clones that showed the presence of a 4.4-kb band and absence of a 1.2-kb band in PCR3 were considered integration events. Number of positive clones/number of total clones
checked.
e Clones that lacked the endogenous 1.2-kb band for the UPRT locus but which did not give the expected band of 4.4 kb, corresponding to insertion of DHFR*, were considered
disruptions. Number of positive clones/number of total clones checked.
f ND, not determined.
Efﬁcient Gene Disruption with CAS9
















tion of DHFR* at the ROP18 locus by PCR (Fig. 4B) and subse-
quent Western blot analysis confirmed the loss of ROP18 expres-
sion (Fig. 4C). All of the CRISPR/CAS9 plasmids used here are
transiently expressed and lack selection for retention in T. gondii,
and such plasmids are normally lost over the first few days in
culture. However, we performed immunofluorescence assays and
Western blot analysis to check the CAS9-GFP expression to see
whether any clones retained the sgROP18 CRISPR plasmid
(which would interfere with the complementation described be-
low). We did not observe any GFP expression in any of the three
clones checked (data not shown), indicating loss of the CRISPR
plasmid. We then generated a complemented line in the GT1
knockout by expressing ROP18with a Ty epitope tag driven by the
IMC1 promoter at the UPRT locus, as described previously (23).
The sgUPRT CRISPR plasmid was used to introduce double-
strand breaks, while the ROP18 expression cassette was flanked by
homology regions to drive homologous integration into the
UPRT locus (Fig. 4D). Following cotransfection, parasites were
selected with FUDR, and single clones were screened for ROP18
expression by immunofluorescence staining. Approximately 20 to
FIG 4 CRISPR/CAS9-mediated disruption of ROP18 in the type I strain GT1. (A) Schematic of CRISPR/CAS9-mediated disruption of ROP18 by insertion of
DHFR*. Transfection of sgROP18 togetherwith theDHFR* amplicon shownwas used to disrupt theROP18 coding region. The purple bar indicates the sgROP18
target region. (B) Diagnostic PCR demonstrating homologous integration in a representative rop18::DHFR* clone compared with the parental line GT1. (C)
Expression of ROP18 in a rop18-disrupted line (rop18::DHFR*) and a complemented line (rop18::DHFR*/uprt::ROP18) determined byWestern blotting. ROP18
was detected by rabbit anti-TgROP18, and GRA7 was detected by mouse anti-TgGRA7 as a loading control. Primary antibodies were detected with Li-Cor
secondary antibodies and anOdyssey imaging system. (D) Schematic showing the complementation of ROP18-deficient parasites by insertion at theUPRT locus
(uprt::ROP18). (E)Diagnostic PCRdemonstrating complementation of ROP18 at theUPRT locus (rop18::DHFR*/uprt::ROP18). (F) Survival curves of parasites
in CD1mice.Wild-type RH andGT1 strains were compared to their respective knockouts (rop18). TheGT1 knockout was complemented to re-express ROP18
(rop18/ROP18) at wild-type levels (see panel C). Mice were injected i.p. with the number of parasites indicated in parentheses, and survival was monitored for
30 days.
Shen et al.
















30% of FUDR-resistant parasites expressed ROP18 (data not
shown), a number that is probably limited by the efficiency of
cotransfection. A representative clone showing a level of ROP18
expression similar to that of wild-type GT1 (Fig. 4C) cells and
correct integration into the UPRT locus (Fig. 4E) was chosen for
further analysis. These results indicate that the CRISPR/CAS9 sys-
tem also works efficiently in genetic backgrounds that have previ-
ously been refractory to genetic manipulations.
To determine the role of ROP18 in the type I GT1 strain, we
injected the rop18 parasites into CD1 mice at different dosages
and monitored the survival of mice for 30 days. For comparison,
we also injected RH and a rop18mutant in this background. As
described previously (9), RHrop18 parasites were only slightly
attenuated, andmice lived only 2 to 3 days longerwhen challenged
with 300 tachyzoites (Fig. 4F). In contrast, most (75%) mice sur-
vived infection at a dose of 300 tachyzoites of GT1rop18 para-
sites, while injection of 3,000 parasites resulted in approximately
60% mortality (Fig. 4F). The reduced virulence of GT1rop18
parasites was fully restored in the complemented line (Fig. 4F).
These results suggest that ROP18 plays a more important role in
mediating pathogenesis in the type I natural isolate GT1 than in
the laboratory strain RH.
DISCUSSION
Although existing genetic tools work well in selected laboratory
strains of T. gondii, natural isolates, in particular those that com-
plete the entire life cycle, are much more refractory to manipula-
tion. To overcome this limitation, we developed a CRISPR/CAS9
system for targeted gene disruption in T. gondii. CRISPR/CAS9
was able to target genes for disruptionwith high efficiency and also
facilitated gene disruption and/or deletion by insertion of a select-
able marker following site-specific targeting using an sgRNA. Re-
markably, gene disruption by insertion of a selectable marker did
not require homology arms for efficient integration, suggesting
that this process occurs byNHEJ. In contrast, when relatively long
regions of homology were used, CRISPR/CAS9 promoted effi-
cient homologous recombination, resulting in complete deletion
of a coding region that spanned a 4-kb region using a single site-
specific break introduced by an sgRNA. Application of CRISPR/
CAS9 to the type I strain GT1, which has previously been refrac-
tory to genetic manipulation, allowed efficient disruption of an
important virulence factor ROP18, as well as complementation by
reintroduction of the gene into a neutral locus. These results dem-
onstrate the utility of CRISPR/CAS9 for genetic manipulations in
diverse genetic backgrounds, without the need to generate specific
lines that have enhanced levels of homologous recombination.
Although reverse genetic technologies for T. gondii are well
developed, the targeting of specific loci is limited by the fact that
recombination tends to occur by nonhomologous integration of
foreignDNA into the chromosome (21, 24, 25). Typically, homol-
ogous recombination requires long homology arms surrounding
a selectable marker of interest to favor double-crossover replace-
ment or single crossover followed by resolution of a pseudodip-
loid to generate knockouts (21, 24). The high frequency of non-
homologous recombination in T. gondii suggests that integration
occurs by chromosomebreaks that are repaired byNHEJ.Double-
strand chromosomal breaks are normally repaired by NHEJ,
which relies on a complex of proteins, including the heterodimer
KU70/KU80, which is conserved in a wide range of organisms
from bacteria to humans (26). Disruption of this system affects
nonhomologous repair but does not affect the process of homol-
ogous recombination. Hence, using ku80 T. gondii lines, it is
possible to achieve homologous recombination rates of nearly
~95%and to target genes for deletion by double crossover (5, 7) or
tag the endogenous locus by single crossover to replace the 3= end
of the gene with an epitope-tagged copy (6). The utility of this
system was further enhanced by importing the positive-negative
selectable marker hypoxanthine-xanthine-guanosine phosphori-
bosyl transferase (HXGPRT), described previously (27), thus al-
lowing markers to be recycled (5). Although this system provides
a very efficient means of gene disruption in T. gondii, it is thus far
limited to two laboratory-adapted strains that represent the type I
(RH strain) (5, 6) and type II (Pru) (7) clonal lineages. However, it
is difficult to extrapolate from these results to infer the possible
roles of genes in other clonal strains or in diverse lineages. There
are also some intrinsic limitations to usingku80mutants, as this
defect results in genome instability, thus limiting the use of certain
selectable markers that may induce mutation (5) and precluding
their use in meiotic crosses. Additionally, studies have implicated
NHEJ in telomere stability (26), such that long-termmaintenance
of ku80 lines may result in genome rearrangements. All of these
limitations make it desirable to find a means of enhancing gene
targeting in T. gondii without the use of modified strains.
Although a relatively recent development, CRISPR/CAS9 has
proven useful for a number of types of genome modification in
model organisms. Site-specific double-strand DNA breaks (DSB)
induced by CRISPR/CAS9 in cultured mammalian cells can be
repaired by either the mutagenic NHEJ, leading to insertion and
deletion mutations in targeted genes, or homologous recombina-
tion in the presence of a donor template to knock in specific gene
alleles or selectionmarkers (18). CRISPR/CAS9 has also been used
to target multiple genes in one step and to perform genomic edit-
ing of specific alleles by homologous recombination (20). In zebra
fish, CRISPR/CAS9 has been used for gene disruption and for
epitope tagging by homologous recombination (although the ef-
ficiency is very low) (16). In Caenorhabditis elegans, CRISPR/
CAS9 was used to insert selectable markers into specific genes
using homology templates containing long flanking (2-kb) arms
(28). CRISPR/CAS9 has also been used to delete large chromo-
somal regions of haploid human cells using two guide RNAs tar-
geting two different regions in the same cell (29). CRISPR/CAS9
stimulated homologous recombination has been used to correct
genetic disorders in a few diseasemodels by replacing themutated
genes with wild-type copies through homology-directed repair
(30, 31).
Here, we imported the CRISPR/CAS9 system into T. gondii to
perform targeted gene disruption and gene deletion. We took ad-
vantage of the fact that CAS9 works efficiently using a single fused
guide RNA consisting of a scaffold RNA and a site-specific RNA
that matches the target gene of interest (14, 32). We engineered
sgRNA that contained 20 bp of direct homology to the gene of
interest positioned upstream of the PAM sequence for CAS9 from
S. pyogenes. CRISPR/CAS9 led to efficient double-strand breaks at
a site corresponding to 17 to 18 bp of the sgRNA, the repair of
which led to small deletions and insertions in the UPRT target.
Althoughwe have not extensively examined the genome ofT. gon-
dii for potential off-target effects due to CRISPR-mediated muta-
tion, this possibility is less of a concern than in mammalian sys-
tems, simply due to the smaller genome and hence decreased
probability of off-targetmatches for 20-bp guide RNAs. Nonethe-
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less, caution should be exercised in the design of gRNAs to ensure
they are unique in the genome and terminate at the NGG PAM
sequence. To address the requirement for sequence specificity, we
tested two sgRNAs that had 2-bpmismatches, engineered close to
the site of the double-strand break that is initiated by CRISPR/
CAS9. These changes decreased the efficiency of disruption of the
target UPRT 200- to 3,000-fold, suggesting that for targeted gene
disruption, the process is highly efficient.
The targeting of UPRT for disruption by CRISPR/CAS9 was
extremely efficient and easily assayed using FUDR resistance.
However, applying this technology to other loci that may lack a
selectable phenotype, or for which reagents might not be available
to assess disruption, will be less straightforward. In this regard, the
ability to introduce a selectablemarker at the site of double-strand
break induced by the sgRNA should provide a highly efficient
means to target any nonessential gene. An added advantage of
CRISPR/CAS9 is that insertion appears not to require homology
arms, as the insertion of DHFR* into the UPRT locus that had
been targeted by an sgRNAwas as efficient regardless of the length
or even presence of homology arms that match the targeted re-
gion. These results strongly suggest that short homology arms do
not drive homologous recombination but instead are inserted by
NHEJ where the fragment provided as a selectable marker is used
to repair the break in the chromosomes introduced by CRISPR/
CAS9. Although we did not verify this here, it is likely that under
these circumstances (i.e., short or no homology regions) the
DHFR* cassette can insert in either orientation, although if the
goal is gene disruption, this does not affect the outcome. In terms
of targeting genes for disruption, CRISPR/CAS9 is much more
efficient for targeted disruption than ku80 lines, which require
homology arms of 500 bp in length for efficient targeting.
Hence, CRISPR/CAS9 should be highly effective for rapid disrup-
tion of genes and for introducing transgenes to specific sites. For
the loci examined here (UPRT and ROP18), we achieved high
frequencies of gene disruption. However, the efficiency may vary
for different genes depending on the specific guide RNA used, the
selection cassette, and the transformation efficiency. The UPRT
locus provides a convenient nonessential locus for targeting that
also provides a means of negative selection. We used this strategy
here to complement the rop18mutant, but in principle it could
be used to introduce any transgene of interest.
Generating clean knockouts of an entire genetic locus is often
desirable to remove any concern that a truncated version of the
RNA or protein may still be generated from a partial disruption.
CRISPR/CAS9 also proved extremely efficient for gene deletion by
homologous recombination at a site that was targeted for a
double-strand break using a site-specific sgRNA. In this case, it
was important to provide relatively long homology arms that lay
outside the gene of interest. Although nearly all of the clones iso-
lated from such experiments showed evidence of disruption of the
targetUPRT locus, only about 50% showed clear evidence of dou-
ble crossovers by homologous recombination. Using simple diag-
nostic PCR screening, it should be possible to isolate clones where
the entire locus has been deleted from experiments pairing an
sgRNA CRISPR plasmid with a template containing long homol-
ogy regions flanking a selectable marker. Generation of such
homology-targeting plasmids by Gatewaymakes this feasible on a
moderately high throughput scale, since the design and construc-
tion of vectors are modular. The selectable marker could also eas-
ily be recycled, by flanking it with loxP sites and introducing Cre
recombinase to remove themarker once the targeted gene disrup-
tion has been achieved (33) (the HXGPRTmarker would provide
the added utility of being both positive and negative selection).
Finally, given the efficiency of CRISPR/CAS9 for targeted gene
disruption using insertion of the DHFR* cassette, this system
might be exploited for genome-wide screens of gene disruptions,
as has recently been done for several systems (34, 35).
A second major advance provided by CRISPR/CAS9 is the ef-
ficient genetic manipulation of diverse T. gondii strains that are
otherwise refractory to transformation. In previous studies, we
identified ROP18 as an important virulence determinant in a ge-
netic cross between the type I strain GT1 and the type III strain
CTG (8). Because of difficulties in generating gene knockouts in
the GT1 line, we instead used a ku80 mutant of RH to test the
role of ROP18 in the type I background (9). Loss of this gene in the
RH strain resulted in only a modest decrease in acute virulence
(9), in contrast to the large difference seen in the acute virulence of
the parental strains (8). Although this discrepancy could be ac-
counted for by other genes, the original mapping studies esti-
mated that ~65% of the acute virulence phenotype was attributed
to ROP18 (8). Using CRISPR/CAS9, we were able to efficiently
disrupt ROP18 in the GT1 strain, revealing that it plays a much
larger role in this background. Although the reasons for this dif-
ference are presently unclear, previous studies have shown that the
RH strain differs from other type I strains in gene expression (11)
and in various growth-related phenotypes in vitro (22), which
might mask the role of specific genes in virulence. In addition,
previous studies have predicted that alleles of ROP18 play a wider
role in virulence of diverse strains, such as those found in South
America (36). However, these studies were based on transgenic
expression of ROP18 alleles in a type III strain, which is normally
hypomorphic for ROP18. CRISPR/CAS9 now offers the possibil-
ity of deleting ROP18 in these lineages, thus providing a better
assessment of its role in pathogenesis.
In addition to working in a wider range of backgrounds,
CRISPR/CAS9 also has obvious advantages in terms of efficiency
of transformation. In the example of ROP18, all 6 randomly se-
lected pyrimethamine-resistant clones proved to be clean knock-
outs. This contrastswith numerous failed efforts to disruptROP18
or KU80 in this background using conventional technology (our
unpublished results, consisting of more than three failed attempts
each by several members of the lab). Moreover, CRISPR/CAS9
provided a rapidmeans of complementing the gene by reinsertion
into theUPRT locus. Random integration is widely used to intro-
duce transgenes in T. gondii, yet it has the disadvantage of not
knowing the precise genetic location of the insertion, thus poten-
tially complicating the interpretation of the phenotype. Efficient
targeting into the UPRT locus, which is a nonessential gene in
T. gondii, provides a neutral location for complementing genes,
and this process was aided by using CRISPR/CAS9. The efficiency
of CRISPR/CAS9 for performing geneticmanipulations in natural
genetic backgrounds extends the power of reverse genetics beyond
a few laboratory strains ofT. gondii. Aswell as encompassing other
members of the clonal lineages, it quite likely will also be applica-
ble to the diverse members of other haplogroups that have re-
cently been described for T. gondii (4). Thus, CRISPR/CAS9 adds
another powerful tool to the repertoire of genetic techniques
available in T. gondii.
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Parasites strains and growth conditions. The T. gondii strains used in
this study were maintained by growth in human foreskin fibroblasts
(HFF) cultured in Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 10 g/ml gentamicin, and
10 mM glutamine (Thermo, Fisher Scientific, Waltham, MA). Wild-type
RH and GT1 and the parasite mutant lines RH ku80 and RH
ku80rop18 were described previously (9). Transgenic parasites were
obtained by electroporation of constructs into cells and selection with
3 M pyrimethamine (Sigma-Aldrich, St. Louis, MO) or 10 M FUDR
(Sigma-Aldrich, St. Louis, MO).
Plasmid construction.All the plasmids and primers used in this study
are listed in Tables S1 and S2 in the supplemental material, and further
details on plasmid construction can be found in the supplemental meth-
ods in the supplementalmaterial. Amap and sequence file for the plasmid
expressing CAS9 and a single guide RNA (sgRNA) targeting the UPRT
gene inT. gondii can be found in Fig. S1 in the supplementalmaterial. The
UPRT-targetingCRISPRplasmid (sgUPRT)was constructed in two steps:
first, the U6 promoter from T. gondii driving expression of the UPRT-
specific sgRNA was cloned into the backbone plasmid pSAG1-Ble-SAG1,
as described in the supplementalmethods. This plasmidwas furthermod-
ified to express the CAS9-NLS-GFP cassette under the SAG1 promoter.
All other CRISPR/CAS9 plasmids were obtained throughQ5mutagenesis
(New England Biolabs, Ipswich, MA) of this plasmid to change theUPRT
targeting gRNA to other specific sgRNAs using primers listed in Table S2.
To generate a plasmid for insertingDHFR* into theUPRT gene, upstream
(750-bp) and downstream (900-bp) regions directly adjacent to the sgU-
PRT target sequence were used to flank DHFR* (24). To generate a con-
struct for deleting the entire coding sequence ofUPRT, flanking regions 5=
(~1 kb) and 3= (~1 kb) outside the coding region were used to surround
the DHFR* cassette. To test the efficiency of short homology regions for
site-specific integration, the DHFR* cassette was amplified using 20-bp
flanking regions from the UPRT locus (surrounding the sgUPRT site)
(Table S2) or the DHFR* cassette was used as an amplicon generated
without homology regions. To generate a construct for disrupting the
ROP18 locus, 5= (820-bp) and 3= (850-bp) regions flanking the sgROP18
target region were used to surround the DHFR* cassette (Table S1). The
ROP18 gene was complemented using a previously described plasmid for
targeting the type I ROP18 allele to the UPRT locus (23).
Site-specific mutagenesis of the UPRT gene. To test the efficiency of
targeted mutation at theUPRT locus, RH strain parasites (107 cells) were
transfected with indicated CRISPR plasmids (Table S1) by electropora-
tion. Transfected cells were allowed to grow for 48 h in the absence of drug
selection and egress naturally. To estimate viability, 200 parasites were
subject to plaque assays in HFF monolayers grown for 7 days without
FUDR. In parallel, aliquots containing 6,000 or 600,000 parasites were
tested for growth in HFF cells in 10 M FUDR. Monolayers were stained
with 0.1% crystal violet, and the number of plaques produced under each
condition was recorded. To confirm the mutations in theUPRT gene, we
obtained FUDR-resistant clones from transfected parasites by subcloning
after 5 to 6 days of selection. DNA from clones was PCR amplified to
obtain the 1.2-kb region flanking the target region (i.e., PCR3) and se-
quenced using the Sanger dideoxy method (Genewiz Inc., South Plain-
field, NJ) (Table S2).
Targeted disruption and deletion of the UPRT gene. To study the
efficiency of CRISPR/CAS9-mediated gene disruption by integration of a
selectablemarker, sgUPRTor sgROP18 targetingCRISPR/CAS9 plasmids
(see Table S1 in the supplemental material) was combined with various
amplicons containing DHFR* expression cassettes for transfection. Am-
plicons were PCR amplified using primers listed in Table S2 in the sup-
plemental material, purified by agarose gel electrophoresis, and extracted
using the Qiaquick gel extraction kit (Qiagen Inc., Valencia, CA). Recov-
ered DNAs were quantified using a Nanodrop 2000 instrument (Nano-
drop Instruments, Wilmington, DE). Mixtures of CRISPR/CAS9 plas-
mids with the purified DHFR* amplicons (5:1 mass ratio) were
cotransfected into RH parasites by electroporation. Pyrimethamine-
resistant parasites were obtained by selection with 3 M pyrimethamine,
and resistant cells were then used for determination of viability and FUDR
resistance by plaque assay as described above. In parallel, single-cell clones
were obtained by limiting dilution, and lysates were generated as de-
scribed previously (4). The specificity of DHFR* integration and loss of
genes by deletion were tested by PCR using primers listed in Table S2.
PCRswere performed using TaqDNApolymerase (NewEngland Biolabs,
Ipswich, MA) in a 25-l reaction mixture containing 2 l of lysate as the
template according to themanufacturer’s directions. In general, reactions
were performed for 35 cycles with denaturation at 95°C for 30 s, annealing
at 57°C for 45 s, and extension for 90 s at 68°C. Products were analyzed by
electrophoresis in agarose gels with ethidium bromide. In some cases,
PCR3 was conducted using Q5 DNA polymerase (New England Biolabs,
Ipswich, MA) to efficiently amplify the inserted DHFR* fragment, giving
a band of 4.4 kb, which was inefficiently amplified using Taq polymerase
under the conditions described above. When PCR3 was performed with
Q5 polymerase, 25-l reaction mixtures containing 2 l template were
amplified for 35 cycles with denaturation at 95°C for 30 s, annealing at
60°C for 30 s, and extension for 3 min at 68°C.
GenerationofROP18knockout andcomplemented lines.Todisrupt
ROP18 in GT1, we cotransfected the sgROP18 CRISPR plasmid along
with an amplicon containing ROP18 homology regions surrounding a
pyrimethamine-resistant DHFR* cassette. Selection by growth for 7 to
8 days in pyrimethamine (3 M) was used to get stably resistant clones
that were subsequently screened by PCR for correct integration ofDHFR*
into the ROP18 locus (see Table S2 in the supplemental material). PCR-
positive clones were further analyzed by Western blotting to confirm the
loss of ROP18 expression. To complement the ROP18-deficient parasites,
we transfected the GT1 rop18::DHFR* parasites with the sgUPRTCRISPR
plasmid (mass ratio, 1:5 [CRISPR/CAS9 to ROP18 complement]) to tar-
get integration to the UPRT locus, along with a previously described
ROP18-complementing plasmid (Ty-tagged ROP18 driven by the IMC1
promoter) (23). Parasites were selected with 10MFUDR for 5 to 6 days,
and single clones were screened by immunofluorescence for Ty expres-
sion using monoclonal antibody (MAb) BB2 (37). Positive clones were
further analyzed by PCR for correct integration at the UPRT locus (see
Table S2) and by Western blotting for ROP18 expression.
Immunofluorescence microscopy. To estimate the frequency of
CRISPR/CAS9-mediated gene disruptions, RH parasites (~107) were
transfected with 7.5 g of indicated CRISPR plasmids (Table S1) and
analyzed by immunofluorescence staining for GFP 24 h posttransfection.
HFF monolayers were fixed with 4% formaldehyde, permeabilized with
0.1% Triton X-100, and incubated with MAb 3E6 (Life Technologies,
Carlsbad, CA) to detect GFP. Parasites were detected with rabbit anti-
TgALD (38). Alexa Fluor 594-conjugated goat anti-rabbit IgG and Alexa
Fluor 488-conjugated goat anti-mouse IgG secondary antibodies (Life
Technologies, Carlsbad, CA) were used to detect primary antibodies. Im-
ages were acquired using a Zeiss Axioskop 2 MOT Plus microscope
equipped with a 63, NA (numerical aperture) 1.6 oil immersion lens
and an AxioCam MRm monochrome camera (Carl Zeiss, Inc., Thorn-
wood, NJ).
Western blotting. To assess ROP18 expression levels, parasite lysates
were subjected toWestern blot analysis as previously described (39). Rab-
bit anti-ROP18 (9) was used to stain ROP18, and mouse anti-GRA7 (40)
was used as a loading control. IRDye800CW-conjugated goat anti-mouse
IgG and IRDye680RD-conjugated goat anti-rabbit IgG were used as sec-
ondary antibodies, and the blot was scanned using the Li-Cor Odyssey
imaging system (Li-Cor Biosciences, Lincoln, NE).
Virulence in laboratory mice.Mice were obtained from The Jackson
Laboratory (Bar Harbor, ME) and maintained in an Association for As-
sessment and Accreditation of Laboratory Animal Care International-
approved facility at Washington University School of Medicine. All ani-
mal experiments were conducted according to the U.S. Public Health
Service Policy on Humane Care and Use of Laboratory Animals, and
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protocols were approved by the Institutional Care Committee at the
School ofMedicine,WashingtonUniversity in St. Louis. To determine the
virulence inmice, parasites were injected intraperitoneally (i.p.) into 8- to
10-week-old female CD-1 mice (5 mice/condition). The survival of mice
was monitored for 30 days, and blood was drawn from surviving mice at
day 30 and tested by enzyme-linked immunosorbent assay (ELISA) to
confirm infection. Mice that were seronegative by ELISA were not in-
cluded in the analysis. Cumulative mortality was plotted as a Kaplan-
Meier survival plot and analyzed in Prism (GraphPad Software, Inc., La
Jolla, CA).
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